221 related articles for article (PubMed ID: 22987091)
1. Gemtuzumab ozogamicin: time to resurrect?
Ravandi F; Estey EH; Appelbaum FR; Lo-Coco F; Schiffer CA; Larson RA; Burnett AK; Kantarjian HM
J Clin Oncol; 2012 Nov; 30(32):3921-3. PubMed ID: 22987091
[No Abstract] [Full Text] [Related]
2. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
3. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
4. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R
Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin: is there room for salvage?
Clarke WT; Marks PW
Blood; 2010 Oct; 116(14):2618-9. PubMed ID: 20930085
[No Abstract] [Full Text] [Related]
6. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
7. Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M; Hangaishi A; Nannya Y; Kurokawa M
Int J Hematol; 2010 Nov; 92(4):673-4. PubMed ID: 20978876
[No Abstract] [Full Text] [Related]
8. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
[TBL] [Abstract][Full Text] [Related]
9. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
10. [Gemtuzumab ozogamicin combined chemotherapy for elderly patients with acute myeloid leukemia].
Ito Y
Rinsho Ketsueki; 2014 May; 55(5):508-17. PubMed ID: 24881915
[No Abstract] [Full Text] [Related]
11. Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia.
Wang ES; Zeidan A; Tan W; Wilding GE; Ford LA; Wallace PK; Hahn TE; Battiwalla M; McCarthy PL; Wetzler M
Leuk Lymphoma; 2012 Oct; 53(10):2085-8. PubMed ID: 21740302
[No Abstract] [Full Text] [Related]
12. Like raising a child.
Berger MS
J Clin Oncol; 2012 Apr; 30(10):1140-1. PubMed ID: 22253464
[No Abstract] [Full Text] [Related]
13. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
14. Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
Gottardi M; Sperotto A; Ghelli Luserna Di Rorà A; Padella A; Cangini D; Giannini MB; Simonetti G; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):395-410. PubMed ID: 32955828
[TBL] [Abstract][Full Text] [Related]
15. Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Mele A; Sparaventi G; Guiducci B; Nicolini G; d'Adamo F; Leopardi G; Delfini C; Piccaluga P; Visani G
Haematologica; 2004 Jun; 89(6 Suppl):ECR18. PubMed ID: 15194554
[No Abstract] [Full Text] [Related]
16. Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia.
Ravandi F; Kantarjian H
Nat Rev Clin Oncol; 2012 May; 9(6):310-1. PubMed ID: 22547217
[No Abstract] [Full Text] [Related]
17. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
18. A single administration of gemtuzumab ozogamicin for molecular relapse of acute promyelocytic leukemia.
Schwarz J; Marková J; Peková S; Trnková Z; Sponerová D; Cetkovský P
Hematol J; 2004; 5(3):279-80. PubMed ID: 15167917
[No Abstract] [Full Text] [Related]
19. Gemtuzumab ozogamicin for acute myeloid leukemia.
Appelbaum FR; Bernstein ID
Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]